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depression. However, our experience, supported by several studies
that were not quoted by Yamaji et al., (1) is that the predominant
ECG manifestation of left main stenosis is diffuse ST depression
in both the inferior and precordial leads (2–4).
It was shown in both the experimental laboratory and in clinical
studies that a sudden obstruction of a left main coronary artery
induces an increase of the end diastolic pressure without
increasing the end diastolic volume, thus shifting the pressure/
volume curve upright (5,6). The sudden increase of the end
diastolic pressure reduces the subendocardial coronary flow,
resulting in a circumferential subendocardial ischemia (6). The
electrical vector is shifted from the epicardium toward the
subendocardium, causing diffuse ST depression with inverted T
waves in the precordial leads on the surface ECG (2,3,7). Lead
aVR faces the cavity of the left ventricle from a right superior
axis and thus records a mirror image of the apical leads V5 and
V6. Hence, if there is ST depression in leads V5 and V6, lead
aVR will usually show ST elevation. This phenomenon is seen
on the ECG in various clinical situations associated with an
increase of the left ventricular end diastolic pressure, such as
tachycardia-induced ischemia and in chronic infarction with
restrictive remodeling (8).
In their study, Yamaji et al. (1) reported on the incidence of ST
elevation in each lead, but not on the incidence of ST depression.
In two of the three cases reported by Frierson et al. (4) there was
ST elevation in lead aVR in addition to marked ST depression in
leads V3 through V6. In the third case with acute ischemia due to
left main stenosis, only mild ST depression was seen in leads V3
through V6 and no ST elevation in lead aVR, supporting the
concept of lead aVR representing the mirror image of leads V5
and V6. Figure 1a of Yamaji et al. (1) shows ST elevation in
leads aVR, aVL and V2, with marked ST depression in the
inferior leads. We have previously reported this pattern to
represent mid-anterior myocardial infarction (MI) caused by
first diagonal branch occlusion (9). In the classic presentation,
there is ST elevation in leads I, aVL and V2, reciprocal ST
depression with negative T waves in the inferior leads, and ST
depression with tall positive T waves in leads V4 and V5
(representing anterior subendocardial ischemia). Four of the
eight patients reported in that study had ST elevation in lead
aVR in the acute phase and six had ST elevation in lead aVR in
the predischarge ECG. All these patients had an occlusion of
the first diagonal branch without stenosis of the left main
coronary artery. Thus, it might be that the ECG in Figure 1a
presented by Yamaji and colleagues (1) represents ischemia
induced by embolization of a thrombus from the left main
coronary artery to the first diagonal branch.
It might be that there are cases in which the “reciprocal” ST
elevation in lead aVR is more prominent than the ST depression
in the leads facing the apex. Previously we reported that “recipro-
cal” ST depression in lead aVL is seen more often than ST
elevation in leads II, III and aVF in the early stages of inferior
acute MI (10).
In conclusion, ST elevation in lead aVR is probably a “recipro-
cal” change to ST depression in leads oriented toward the cardiac
apex. Although ST elevation in lead aVR may occur with left main
coronary artery occlusion, it may also be detected in other
situations with ST depression, such as infarction caused by a first
diagonal branch occlusion.
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REPLY
Our series presented all the characteristics of acute myocardial
infarction (AMI), including elevated creatine kinase (CK), hemo-
dynamic deterioration, associated with acute left main coronary
artery (LMCA) obstruction, not LMCA stenosis (1). Patients in
the reports published by Sclarovsky et al. (2,3) showed manifesta-
tions of unstable angina. Therefore, we do not believe that 12-lead
electrocardiogram (ECG) findings in our patients (LMCA AMI
patients) can be compared with findings in their patients (LMCA
unstable angina patients). For this reason, our study did not refer
to the reports by Sclarovsky et al. (2,3). In our patients, ST-
segment depression was found in leads V5 and V6 in 38% (6/16)
and 44% (7/16) of patients, respectively, whereas lead aVR
ST-segment elevation was found in 88% (14/16) of patients.
Moreover, lead aVR ST-segment shift was not correlated with
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ST-segment depression in lead V5 or lead V6. Stepwise multivar-
iate discriminant analysis did not select V5 or V6 as leads in which
ST-segment shift distinguished patients with acute LMCA ob-
struction from patients with acute obstruction of the left anterior
descending coronary artery (LAD). Therefore, we do not consider
ST-segment depression in leads V5 and V6 to be a characteristic
finding in “LMCA AMI patients.” The findings of our patients
indicated that lead aVR ST-segment elevation is not a mirror
image of ST-segment depression in leads V5 and V6.
Engelen et al. (4) reported that lead aVR ST-segment elevation
was observed in acute obstruction of the LAD proximal to the
major septal branch but not in acute LAD obstruction distal to the
major septal branch. They concluded that lead aVR ST-segment
elevation associated with proximal LAD obstruction was caused by
transmural ischemia of the basal part of the septum. Our findings
were completely in agreement with the findings by Engelen et al.
(4).
Our previous study (5) clearly demonstrated that isolated
diagonal branch occlusion caused ECG abnormalities in leads I
and aVL, while less frequently causing changes in the precordial
leads compared with those caused by acute LAD obstruction,
indicating that leads I and aVL represent myocardium perfused by
the diagonal branch. Acute LMCA obstruction causes ischemia in
myocardium perfused by the diagonal branch. Our finding that
ST-segment elevation in lead aVL was observed in high incidence
in LMCA AMI patients was completely in agreement with our
previous study (5). The ST-segment elevation in leads aVL and I
in LMCA AMI patients was caused by ischemia in myocardium
perfused by the diagonal branch associated with acute LMCA
obstruction.
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Cyclooxygenase-2 Inhibitors and
Cardiovascular Thromboembolic Events
In the recent perspective published by Bing and Lomnicka in the
Journal (1), several hypotheses were given for why cyclooxygenase-2
(COX-2) inhibitors may cause cardiovascular events. The investi-
gators even stated in their abstract that their report “confirms
evidence that selective nonsteroidal anti-inflammatory drugs
[NSAID] such as celecoxib can lead to thrombotic cardiovascular
events.” In fact, there are no data provided by Bing and Lomnicka
(1) nor from the clinical literature that clinical cardiovascular
events, defined as acute myocardial infarction, stroke and cardio-
vascular death, are increased owing to the COX-2 inhibitor,
celecoxib. Thus, I believe that their study is potentially misleading
to the readership of the Journal.
Using well-known basic pharmacology literature as a resource,
Bing and Lomnicka (1) stated that selective COX-2 inhibitors
attenuate the production of prostacylin, but do not alter throm-
boxane A2 levels and therefore may theoretically tip the balance in
favor of thrombosis. Thus, certain types of high-risk patients
treated with COX-2 inhibitors could be predisposed to increases in
cardiovascular events. To further support their hypothesis, how-
ever, they use the highly controversial post hoc analysis of data
from Mukherjee et al. (2), which suggested that the COX-2
inhibitors celecoxib and rofecoxib had a higher myocardial infarc-
tion event rate compared to an entirely unrelated, separate cohort
of generally healthy individuals in the placebo arm of four primary
prevention trials using aspirin (2). The sources of the pooled
analyses for the COX-2 inhibitors from the analysis of Mukherjee
et al. (2) derived from the Celecoxib Long-term Arthritis Safety
Study (CLASS) (3) and Vioxx Gastrointestinal Outcomes Re-
search (VIGOR) (4) trials using celecoxib and rofecoxib, respec-
tively, and two clinical trials that compared rofecoxib with a
nonselective NSAID, nabumetone. The CLASS and VIGOR
trials were conducted in approximately 8,000 arthritis patients each
and compared the gastrointestinal safety of the COX-2 inhibitors
versus the widely used NSAIDs, ibuprofen and diclofenac (in
CLASS) and naproxen (in VIGOR) for a median period of about
nine months in each trial.
A number of errors made by Mukherjee et al. (2) have now been
documented by numerous letters to the editor of JAMA in
December 2001. For example, patients in the CLASS trial who
were treated with low-dose aspirin (owing to prior cardiac or
cerebrovascular disorders) were compared to placebo patients who
had no known prior history of myocardial infarction (MI) from
four primary prevention trials evaluating the beneficial effects of
aspirin. The annual MI rates reported for celecoxib in CLASS and
rofecoxib in VIGOR by Mukherjee et al. for the entire group were
0.7% to 0.8% compared to a rate of 0.52% of MI observed in the
placebo group from the primary prevention trials. When the
patients who were nonusers of aspirin in the CLASS trial (about
3,100 patients) on celecoxib were assessed, the incidence of MI was
just 0.3%.
We recently reported on an extensive analysis of these throm-
bovascular events in the CLASS trial (5); that study showed no
evidence that high doses of celecoxib (400 mg twice daily)
increased the risk of acute MI, stroke, or venous thromboembolic
events compared to the conventional NSAIDs, ibuprofen or
diclofenac. This was true for the entire study population, both in
patients not taking aspirin and in patients taking aspirin. Similarly,
there have been no data from the premarketing clinical trials that
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